 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Long-term outcomes of rituximab combined with lenalidomide or chemotherapy in follicular lymphoma

J Clin Oncol: Long-term outcomes of rituximab combined with lenalidomide or chemotherapy in follicular lymphoma

 Last Update: 2022-08-19
 Source: Internet
 Author: User

Tags

advanced structural technologies

advanced tbs

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Immunochemotherapy remains the first-line gold standard for patients with follicular lymphoma (FL) requiring systemic therapy; however, FL has now been demonstrated to be immune to nonchemotherapy regimen.

The RELEVANCE trial is a Phase 3 clinical trial to compare lenalidomide + rituximab (R2) vs rituximab + chemotherapy (R-chemo) in patients with previously untreated advanced FL efficacy and safet.

In this trial, patients with stage 1-3a FL were randomized (1:1) to R2 or R-chemotherapy followed by rituximab maintenanc.

After a median follow-up of 72 months, the 6-year PFS in the R2 and R-chemotherapy groups was 60% and 59%, respectively (hazard ratio [HR] 03.

The overall response rates after progression in the R2 and R-chemotherapy groups were 61% and 59%, respectively, and the estimated 5-year survival rates after progression were 69% and 74%, respectivel.

In conclusion, in previously untreated patients with advanced follicular lymphoma, the R2 regimen showed comparable durable efficacy and safety to R-chemotherapy, and could be an alternative to no chemotherap.

Original source:

Franck Morschhauser, et a.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.